Stirling goes back to the drawing board
Monday, 07 March, 2005
Stirling Products (ASX:STI) will extend its proof-of-concept studies to include a more direct delivery method after analysis of levels of its beta agonist ST810, a single enantiomer form of salbutamol, in the bloodstream of merino lambs showed that the growth promoter was not getting into the bloodstream.
Significantly, the positive control, a mixed enantiomer form of salbutamol, also failed to get into the bloodstream.
Managing director Calvin London said that as a result, sufficient plasma levels of the drug were not achieved, and no significant physical effects such as reduction in fat or increase in muscle were observed.
Now, the company plans to look at using a more precise controlled release delivery directly into the tissue. The follow-on study is expected to begin in April.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
